Immunogenicity and safety of mixed COVID-19 vaccine regimens in patients with immune-mediated inflammatory diseases: a single-centre prospective cohort study.
Carol A HitchonChristine MesaCharles N BernsteinKathryn C FitzgeraldCatherine CardSheila F O'BrienJohn KimPublished in: BMJ open (2023)
Heterologous COVID-19 vaccination improves seroconversion rates following a vector vaccine and does not lead to IMID disease flare. IMIDs benefit from at least three vaccines.